Ftse Mib
33.414,56
0,46%
DAX
19.626,45
1,05%
S&P 500
6.032,38
0,56%
NASDAQ
19.218,17
0,83%
Bitcoin
96.327,65
-0,11%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Menlo Therapeutics Inc (MNLO) Menlo Therapeutics Inc (MNLO) Notizie

MNLO

Menlo Therapeutics (MNLO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNLO
DataOraFonteTitoloSimboloCompagnia
02/06/202322:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MNLOMenlo Therapeutics Inc
11/05/202322:25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:MNLOMenlo Therapeutics Inc
11/05/202322:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MNLOMenlo Therapeutics Inc
14/03/202322:14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:MNLOMenlo Therapeutics Inc
25/11/202220:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MNLOMenlo Therapeutics Inc
18/11/202223:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:MNLOMenlo Therapeutics Inc
14/11/202222:51Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:MNLOMenlo Therapeutics Inc
28/07/202222:31Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:MNLOMenlo Therapeutics Inc
12/05/202223:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MNLOMenlo Therapeutics Inc
15/02/202212:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:MNLOMenlo Therapeutics Inc
14/01/202223:22Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:MNLOMenlo Therapeutics Inc
21/06/202123:19Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:MNLOMenlo Therapeutics Inc
17/05/202112:30Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MNLOMenlo Therapeutics Inc
06/05/202123:03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:MNLOMenlo Therapeutics Inc
20/04/202122:49Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:MNLOMenlo Therapeutics Inc
04/03/202122:32Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MNLOMenlo Therapeutics Inc
02/02/202121:17Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:MNLOMenlo Therapeutics Inc
05/06/202022:35Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:MNLOMenlo Therapeutics Inc
22/05/202014:30Business WireRobbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Menlo Therapeutics Inc. Securities SettlementNASDAQ:MNLOMenlo Therapeutics Inc
16/04/202018:47Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:MNLOMenlo Therapeutics Inc
03/03/202022:05GlobeNewswire Inc.Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial ResultsNASDAQ:MNLOMenlo Therapeutics Inc
26/02/202013:30GlobeNewswire Inc.Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown OriginNASDAQ:MNLOMenlo Therapeutics Inc
26/02/202001:01GlobeNewswire Inc.Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chr...NASDAQ:MNLOMenlo Therapeutics Inc
05/02/202014:30GlobeNewswire Inc.Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Pso...NASDAQ:MNLOMenlo Therapeutics Inc
07/01/202022:49Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:MNLOMenlo Therapeutics Inc
06/01/202022:48Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:MNLOMenlo Therapeutics Inc
16/12/201923:15Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:MNLOMenlo Therapeutics Inc
04/12/201923:20Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:MNLOMenlo Therapeutics Inc
27/11/201914:00GlobeNewswire Inc.Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare ConferenceNASDAQ:MNLOMenlo Therapeutics Inc
12/11/201923:09PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.NASDAQ:MNLOMenlo Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNLO

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BAMI
Banco BPM
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
MONC
Moncler
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
MB
Mediobanca Banca di Cred...
BIT
G
Generali
BIT
BPE
Bper Banca
BIT
SPM
Saipem
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network